Rare disease biopharma commercializing liver and metabolic therapies
Mirum Pharmaceuticals markets rare disease medicines, including LIVMARLI, CHOLBAM and CTEXLI, while advancing late-stage liver disease candidates. Hiring is accelerating and overwhelmingly sales-led, with field teams focused on closing patient identification and diagnosis gaps. The stack pairs Veeva, Salesforce and Komodo for commercial targeting with Snowflake, Power BI and Tableau for analytics, and the company is adopting DocuSign CLM and Agiloft to formalize contract management.
Notable leadership hires: Regional Business Director, Scientific Director, Director IT
Mirum Pharmaceuticals is a public rare disease company headquartered in Foster City, CA, founded in 2018, with 201–500 employees. Its approved products are LIVMARLI (maralixibat) for Alagille syndrome and PFIC, CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis. The clinical pipeline includes volixibat for PSC and PBC, brelovitug for chronic hepatitis delta virus, and MRM-3379 for Fragile X syndrome. The company sells to specialist treatment centers and hires across the United States, Switzerland, Italy and Germany.
Mirum uses Veeva, Veeva QMS, Salesforce, Komodo, Snowflake, Power BI, Tableau, SAS, CDISC, Electronic Data Capture, Adaptive Planning, Concur, Okta, Intune, Box and Greenhouse, and is adopting DocuSign CLM and Agiloft.
Yes. Hiring is accelerating and heavily sales-focused, including Regional Business Director roles, with smaller openings in legal, marketing and healthcare functions.
Mirum is hiring in the United States, Switzerland, Italy and Germany, with headquarters in Foster City, California.
Other companies in the same industry, closest in size
Mirum Pharmaceuticals, Inc.'s technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.